ScripsAmerica's CEO Issues Positive Outlook for 2013 With Significant Developments Expected During the First Quarter

NEW CASTLE, Del., Dec. 3, 2012 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (OTCBB:SCRC), a leading supplier of prescription, OTC and nutraceutical drugs, today announced that its CEO, Bob Schneiderman, issued a very positive outlook for 2013, citing how the Company expects to finalize the pending acquisition of Marlex Pharmaceuticals and launch its RapiMed children's pain reliever during the first quarter.

Mr. Schneiderman discussed the Company's future during an interview with "The News Journal," also known as, for an article that was featured in the publication's November 25th edition. Titled "ScripsAmerica is gearing for 2013 RapiMed launch," the feature also highlights the fact that ScripsAmerica could potentially double its revenue during 2013 as a result of these significant developments and that management's goal is to implement a regional launch of the RapiMed product line shortly after the beginning of the year.

The primary focus of the article, however, is how ScripsAmerica's acquisition of its current packager, Marlex Pharmaceuticals, is expected to immediately increase the Company's profits by 10 to 15 percent. Additionally, a recent $25 million contract secured by Marlex with the U.S. Department of Homeland Security, will substantially increase ScripsAmerica's revenues when the acquisition is finalized.

"The News Journal" is owned by Gannett Company, Inc., a publicly traded media holding company and the largest U.S. newspaper publisher as measured by total daily circulation. Headquartered in Tysons Corner, Virginia, Gannett's assets include the national newspaper USA Today and the weekly USA Weekend.

About ScripsAmerica, Inc.

ScripsAmerica, Inc. delivers pharmaceutical products to a wide range of end users across the health care industry, including physicians' offices, retail pharmacies, long-term care sites, hospitals, and Government and home care agencies through the largest pharmaceutical distributor in North America, McKesson Corporation. Current therapeutic categories serviced by the Company include pain, arthritis, prenatal, urinary, and hormonal replacement drugs. Other customers of ScripsAmerica include Cardinal Health, Curtis Pharmaceuticals, MedVet and the United States Veterans Administration.

For more information please visit:

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: 888-959-7095Source:ScripsAmerica, Inc.